Compare IKT & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | TBI |
|---|---|---|
| Founded | 2008 | 1985 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.9M | 311.4M |
| IPO Year | 2020 | 1995 |
| Metric | IKT | TBI |
|---|---|---|
| Price | $1.97 | $8.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $6.00 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 424.9K | 220.6K |
| Earning Date | 11-13-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.76 | ★ 61.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.10 |
| Revenue Next Year | $33.33 | $3.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $3.18 |
| 52 Week High | $2.61 | $11.03 |
| Indicator | IKT | TBI |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 42.62 |
| Support Level | $1.93 | $8.63 |
| Resistance Level | $2.13 | $8.90 |
| Average True Range (ATR) | 0.10 | 0.38 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 16.84 | 5.17 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.